

ZurzuvaeTM Prior Authorization Request Form DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)			
Member Name:			Provider Name:			
Insurance ID#:			NPI#:		Specialty:	
Date of Birth:			Office Phone:			
Street Address:			Office Fax:			
City:	State:	Zip:	Office Street Address:			
Phone:			City:	State:		Zip:
Medication Information (required)						
Medication Name:			Strength:	Dosag		orm:
Check if requesting brand			Directions for Use:			
Check if request is for continuation of therapy						
Clinical Information (required)						
 Select the diagnosis and list the rating scale and score below: Diagnosis of severe postpartum depression as indicated by DSM-5 criteria and/or an appropriate depression rating scale (e.g., HAM-D, MADRS, PHQ-9, etc.) Diagnosis of mild to moderate postpartum depression as indicated by DSM-5 criteria and/or an appropriate depression rating scale (e.g., HAM-D, MADRS, PHQ-9, etc) Trial and failure, contraindication or intolerance to at least one oral SSRI or SNRI (e.g., escitalopram, duloxetine, etc) List SSRI or SNRI tried and duration If disqualifying agents due to contraindications alone (without history of previous failed therapy), contraindications to both SSRI and SNRI classes is required. Documentation must be submitted indicating reasoning behind each contraindication. List the contraindications for SSRI and SNRI 						
Other diagnosis:			ICD-10 Code(s):			
Clinical information: When was the onset of symptoms? Provide date: When was the delivery date? Provide date: Has the patient been treated with brexanolone (IV formulation)? □ Yes □ No If yes, date:						
 Prescriber attests that the patient has been counseled and has agreed to adhere to the following: Patient will follow instructions to not drive or operate machinery until at least 12 hours after taking each dose of Zurzuvae for the duration of the 14-day treatment course and that patients are informed that they may not be able to assess their own driving competence, or the degree of driving impairment caused by Zurzuvae Patient has ceased lactating or breastmilk produced will not be used for feedings during treatment and up to 7 days following last dose Females of reproductive potential should be advised to use effective contraception during treatment and for 1 week after the final dose Therapy will not be used in the same pregnancy as brexanolone (Zulresso) 						
this review?						

Please note:

This request may be denied unless all required information is received. For urgent or expedited requests please call 1-855-401-4262. This form may be used for non-urgent requests and faxed to 1-844-403-1029.

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately. Office use only: Zurzuvae SouthDakotaMedicaid 2024April